2Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. Lancet,2002,360 : 7-22.
3Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in ld randomised trials of statins. Lancet,2005, 366 : 1267-1278.
4Smith SC Jr,Allen J,Blair SN ,et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease : 2006 update. Circulat on, 2006,113:2363-2372.
5Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III:a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prey Rehabil,2009,16 : 121-137.
6Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease ( PROSPER ) : a randomised controlled trial. Lancet,2002,360 : 1623-1630.
7Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med,2006,355: 549-559.
8Niu S, Zhao D, Zhu J, et al. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China(BRIG) Project. American Heart Journal, 2009,157 : 709-715.
9John R. Crouse Ⅲ,Joel S. Raichlen,Ward A. Riley,Gregory W. Evans,Mike K. Palmer,Daniel H. O＇ Leary,Diederick E. Grobbee,Michiel L. Bots,李军（译）.瑞舒伐他汀对存在亚临床动脉粥样硬化的低危人群颈动脉内膜中层厚度进展的影响——METEOR试验[J].美国医学会杂志（中文版）,2007,26(4):208-216. 被引量：45
